The 26 references in paper E. PANCHENKO P., Е. ПАНЧЕНКО П. (2017) “ИЗМЕНИЛИСЬ ЛИ НАШИ ПРЕДСТАВЛЕНИЯ О НЕОБХОДИМОСТИ КЛОПИДОГРЕЛА В ЛЕЧЕНИИ КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ С ПОЯВЛЕНИЕМ БОЛЕЕ МОЩНЫХ АНТИАГРЕГАНТОВ? // HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS?” / spz:neicon:aterotromboz:y:2017:i:2:p:32-42

1
Rosamond W et al. Heart Disease and Stroke Statistics—
(check this in PDF content)
2
08 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation,2008, 117: e25–e146. 2. Nichols M, Townsend N, Scarborough P & Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J,2014, 35: 2950–9.
(check this in PDF content)
3
Benjamin EJ et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation,2017, 135: e146–e603.
(check this in PDF content)
4
Lopez AD, Mathers CD, Ezzati M, Jamison DT & Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet (London, England),2006, 367: 1747–57.
(check this in PDF content)
5
Панченко Е.П. Результаты трёхлетнего наблюдения за амбулаторными больными с клиническими проявлениями атеротромбоза (анализ российской популяции регистра REACH). Кардиология, 2009, 10: 9-14.
(check this in PDF content)
6
Steg PG, Bhatt DL, Wilson PWF et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA,2007, 297: 1197–1206.
(check this in PDF content)
7
CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet,1996, 348: 1329-39.
(check this in PDF content)
8
Yusuf S et al. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N. Engl. J. Med.,2001, 345: 494–502.
(check this in PDF content)
9
Sh.Mehta,S.Yusuf, R.Peters et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet,2001, 358: 527-33.
(check this in PDF content)
10
Sabatine M et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with Elevation. N Engl J Med, 2005, March 9 352.
(check this in PDF content)
11
COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet,2005: 1607-21.
(check this in PDF content)
12
Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acure coronary syndromes. N Engl J Med, 2009, 361(11): 1045-1057.
(check this in PDF content)
13
Wiviot SD, Braunwald E, McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357: 2001-15.
(check this in PDF content)
14
Mega J, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEngl J Med, 2012, 366: 9-11.
(check this in PDF content)
15
Mauri L, Kereiakes D, Yeh R et al. Twelve or 12 months of dual antiplatelet therapyafter drug-eluting stents. N Engl J Med, 2014, 371: 2155-2166.
(check this in PDF content)
16
Bonaca M, Bhatt D, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med, 2015, 372: 1791–800.
(check this in PDF content)
17
Bhatt DL et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N. Engl. J. Med.,2006, 354: 1706–1717.
(check this in PDF content)
18
Stone GW, Maehara A, Lansky AJ et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med, 2011, 364: 226-235.
(check this in PDF content)
19
Udell JA, Bonaca M, Collet J-Ph et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: acollaborative meta-analysis of randomized trials. Eur Heart Journal, doi:10.1093/eurheartj/ehv443.
(check this in PDF content)
20
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. doi:10.1093/eurheartj/ehx393.
(check this in PDF content)
21
2017 ESC fosed update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. doi:10.1093/eurheartj/ehx419.
(check this in PDF content)
22
Bergmeijer Th, Janssen P, Oevelen M et al. Inciedence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience. Cardiology, 2017, 138: 164-167.
(check this in PDF content)
23
Biscaglia S, Campo G, Pavasini R et al. Occurrence, causes and outcome after switching from ticagrelor to clopidogrel in real-life scenario: data from a prospective registry. Platelets, 2016. Doi:10.3109/09537104.2015.1119815.
(check this in PDF content)
24
Zettler M, Peterson E, McCoy L et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among mocardial infarction patients: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATEACS) obsevational study. Am Heart J, 2017, 183: 62-8.
(check this in PDF content)
25
Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart Journal,2017. doi:10.1093/eurheartj/ehx175.
(check this in PDF content)
26
International Expert Consensus on Switching Platelet P2Y12Receptor — Inhibiting Therapies. Circulation, 2017, 136: 00–00. DOI: 10.1161/CIRCULATIONAHA.117.031164.
(check this in PDF content)